Home - Chinese Journal of Cancer Research

2019 Impact Factor of CJCR: 4.135
Journal Citation Reports®, Clarivate Analytics

Cancer burden and trends in China: A review and comparison with Japan and South Korea

Cancer is the leading cause of death worldwide. Distinct geographic disparities exist in cancer burden across the world. China, Japan, and South Korea are all located in East Asia. As neighboring countries, Japan and South Korea share similar genetic backgrounds and similar culture with China. Also, in terms of cancer burden, these three countries are all facing a heavy burden of upper digestive tract cancers. This article provides an overview of cancer burden and trends in China by comparing with Japan and South Korea. Comparison among these three countries for the cancer burden and trends could be useful to track the effectiveness of national screening programs and to identify modifiable risk factors. The results can serve as a scientific reference for cancer control policy planning.

重磅来袭——中国国家卫生健康委员会肿瘤诊疗规范英文版！！！（2018年版）

为了适应我国肿瘤领域面临的发展新形势，向国际展示我国肿瘤诊疗的规范化和精准化，推动国内外肿瘤学领域的学术交流，《中国癌症研究》英文杂志(Chinese Journal of Cancer Research，CJCR)组织我国肿瘤领域知名专家学者对国家卫生健康委员会（National Health Commission of the People’s Republic of China, NHCPRC）修订的肿瘤诊疗规范（2018年版）进行编译并出版，以促进我国肿瘤临床研究成果与诊疗经验的国际传播与交流。我们希望通过对肿瘤诊疗规范的编译能够更好地推动全国临床肿瘤学科的规范化建设，帮助各级医务人员提高诊治和研究水平，同时能将更多国际水准、中国特色的研究成果和治疗意见推向国际，造福更多的肿瘤患者。

Cancer incidence and mortality in China, 2014

In 2017, National Central Cancer Registry of China (NCCRC) updated nationwide cancer statistics using population-based cancer registry data in 2014 collected from all available cancer registries. There are 449 cancer registries submitted cancer registry data in 2014, among which 339 registries’ data met the criteria of quality control and were included in analysis. These cancer registries covered 288,243,347 population, accounting for about 21.07% of the national population in 2014. Numbers of nationwide new cancer cases and deaths were estimated using calculated incidence and mortality rates and corresponding national population stratified by area, sex, age group and cancer type. The world Segi’s population was applied for age-standardized rates. Heavy cancer burden and its disparities between area, sex and age group pose a major challenge to public health in China. Nationwide cancer registry plays a crucial role in cancer prevention and control.

Cancer incidence in Beijing, 2014

To analyze cancer incidence data in Beijing in 2014 and temporal trends for selected common cancers during 2005 and 2014. A total of 144 secondary and tertiary hospitals reported newly diagnosed cancer cases to Beijing Cancer Registry, which covers 13 million residents in Beijing. The cancer incidence rate was calculated in strata by cancer type, sex, age group and area. The population composition of China in 1982 and Segi’s population structure were used to calculate age-standardized rates. Extensive procedures were used to assure the quality of the data. A total of 45,300 new cancer cases were diagnosed in Beijing in 2014. The incidence rate was 341.92/100,000 (343.50/100,000 in males, 340.33/100,000 in females). Cancer remains an important public health problem. Actions should be taken to diminish total cancer incidence in Beijing.

‹ ›

Vol 32, No 3 (June 2020)

Review Article

Current status of esophageal cancer treatment

Tania Triantafyllou, Bas P L Wijnhoven

Pages: 271-286 HTML

Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer: Current evidence and future perspectives

Zhening Zhang, Tong Xie, Xiaotian Zhang, Changsong Qi, Lin Shen, Zhi Peng

Pages: 287-302 HTML

Immune checkpoint inhibitors in malignant lymphoma: Advances and perspectives

Ningjing Lin, Yuqin Song, Jun Zhu

Pages: 303-318 HTML

Impact of enteroscopy on diagnosis and management of small bowel tumors

Adriana Vaz Safatle-Ribeiro, Ulysses Ribeiro Jr.

Pages: 319-333 HTML

Original Article

Low-depth whole genome sequencing reveals copy number variations associated with higher pathologic grading and more aggressive subtypes of lung non-mucinous adenocarcinoma

Zheng Wang, Lin Zhang, Lei He, Di Cui, Chenglong Liu, Liangyu Yin, Min Zhang, Lei Jiang, Yuyan Gong, Wang Wu, Bi Liu, Xiaoyu Li, David S Cram, Dongge Liu

Pages: 334-346 HTML

Adipocyte-derived SFRP5 inhibits breast cancer cells migration and invasion through Wnt and epithelial-mesenchymal transition signaling pathways

Wenzhong Zhou, Chunmiao Ye, Liang Li, Liyuan Liu, Fei Wang, Lixiang Yu, Fei Zhou, Yujuan Xiang, Yongjiu Wang, Gengshen Yin, Zhongbing Ma, Qinye Fu, Qiang Zhang, Dezong Gao, Shuya Huang, Zhigang Yu

Pages: 347-360 HTML

Effectiveness of second-line anti-HER2 treatment in HER2-positive metastatic breast cancer patients previously treated with trastuzumab: A real-world study

Wei Zhao, Li Bian, Tao Wang, Shaohua Zhang, Jianbin Li, Fengrui Xu, Zefei Jiang

Pages: 361-369 HTML

Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors

Huiping Li, Rongrui Liu, Bin Shao, Ran Ran, Guohong Song, Ke Wang, Yehui Shi, Jihong Liu, Wenjing Hu, Fu Chen, Xiaoran Liu, Gairong Zhang, Chuanhua Zhao, Ru Jia, Quanren Wang, Hope S. Rugo, Yifan Zhang, Guangze Li, Jianming Xu

Pages: 370-382 HTML

Value of multi-quadrants biopsy: Pooled analysis of 11 population-based cervical cancer screening studies

Yuqian Zhao, Fanghui Zhao, Shangying Hu, Xun Zhang, Wenhua Zhang, Qinjing Pan, Julia C Gage, Rengaswamy Sankaranarayanan, Youlin Qiao

Pages: 383-394 HTML

Clinical and functional comparison of dynamic hip screws and intramedullary nails for treating proximal femur metastases in older individuals

Hua Gao, Xiaodong Bai, Wentao Chen, Yadong Li, Liang Zhao, Changgui Liu, Zhenyu Liu, Baojun Wang

Pages: 395-402 HTML

CSCO Guidelines

Updates in version 2020 of CSCO guidelines for colorectal cancer from version 2019

Shanshan Weng, Ying Yuan, Xicheng Wang, Gong Chen, Yi Wang, Weiqi Sheng, Xinxiang Li, Aiping Zhou, Zhen Zhang, Guichao Li, Sanjun Cai, Ruihua Xu, Jin Li, Suzhan Zhang

Pages: 403-407 HTML

Commentary

An organoids biobank for recapitulating tumor heterogeneity and personalized medicine

Hui Yang, Ning Zhang, Yu-Cun Liu

Pages: 408-413 HTML

Corrigendum

Corrigendum to Clinicopathological analysis of early-stage breast cancer patients that meet indications for BRCA1/2 genetic testing

Pages: 414 HTML

Guidelines

Chinese consensus guidelines for diagnosis and management of gastrointestinal stromal tumor

Jian Li, Yingjiang Ye, Jian Wang, Bo Zhang, Shukui Qin, Yingqiang Shi, Yulong He, Xiaobo Liang, Xiufeng Liu, Ye Zhou, Xin Wu, Xinhua Zhang, Ming Wang, Zhidong Gao, Tianlong Lin, Hui Cao, Lin Shen, Chinese Society of Clinical Oncology (CSCO) Expert Committee on Gastrointestinal Stromal Tumor

Pages: 281-293 HTML

CSCO Guidelines

Updates in version 2020 of CSCO guidelines for colorectal cancer from version 2019

Shanshan Weng, Ying Yuan, Xicheng Wang, Gong Chen, Yi Wang, Weiqi Sheng, Xinxiang Li, Aiping Zhou, Zhen Zhang, Guichao Li, Sanjun Cai, Ruihua Xu, Jin Li, Suzhan Zhang

Pages: 403-407 HTML

Updates in version 2019 of CSCO guidelines for colorectal cancer from version 2018

Ying Yuan, Xicheng Wang, Gong Chen, Yi Wang, Weiqi Sheng, Xinxiang Li, Aiping Zhou, Zhen Zhang, Guichao Li, Sanjun Cai, Ruihua Xu, Jin Li, Suzhan Zhang

Pages: 423-425 HTML

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for head and neck cancer 2018 (English version)

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for head and neck cancer working group

Pages: 84-98 HTML

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for persistent/recurrent and metastatic differentiated thyroid cancer 2018 (English version)

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for persistent/recurrent and metastatic differentiated thyroid cancer working group

Pages: 99-116 HTML

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer 2018 (English version)

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer working group

2019 Impact Factor of CJCR: 4.135Journal Citation Reports®, Clarivate Analytics

Cancer burden and trends in China: A review and comparison with Japan and South Korea

重磅来袭——中国国家卫生健康委员会肿瘤诊疗规范英文版！！！（2018年版）

Cancer incidence and mortality in China, 2014

Cancer incidence in Beijing, 2014

About cjcr

Advertising

Contact us

Review Article

Original Article

CSCO Guidelines

Commentary

Corrigendum

Guidelines

CSCO Guidelines

NHCPRC Guidelines

Virtual Special Issues

Beijing Cancer Hospital

China Anti-cancer Association

Chronic Diseases and Translational Medicine

2018 CGCC

2019 Impact Factor of CJCR: 4.135
Journal Citation Reports®, Clarivate Analytics